• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DNAJ 热休克蛋白家族 B 成员 9 是纤维状 GN 的新型生物标志物。

DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.

机构信息

Departments of Health Sciences Research.

Laboratory Medicine and Pathology, and.

出版信息

J Am Soc Nephrol. 2018 Jan;29(1):51-56. doi: 10.1681/ASN.2017030306. Epub 2017 Nov 2.

DOI:10.1681/ASN.2017030306
PMID:29097623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5748911/
Abstract

Fibrillary GN (FGN) is a rare primary glomerular disease. Histologic and histochemical features of FGN overlap with those of other glomerular diseases, and no unique histologic biomarkers for diagnosing FGN have been identified. We analyzed the proteomic content of glomeruli in patient biopsy specimens and detected DnaJ heat shock protein family (Hsp40) member B9 (DNAJB9) as the fourth most abundant protein in FGN glomeruli. Compared with amyloidosis glomeruli, FGN glomeruli exhibited a >6-fold overexpression of DNAJB9 protein. Sanger sequencing and protein sequence coverage maps showed that the DNAJB9 protein deposited in FGN glomeruli did not have any major sequence or structural alterations. Notably, we detected DNAJB9 in all patients with FGN but not in healthy glomeruli or in 19 types of non-FGN glomerular diseases. We also observed the codeposition of DNAJB9 and Ig- Overall, these findings indicate that DNAJB9 is an FGN marker with 100% sensitivity and 100% specificity. The magnitude and specificity of DNAJB9 overabundance in FGN also suggests that this protein has a role in FGN pathogenesis. With this evidence, we propose that DNAJB9 is a strong biomarker for rapid diagnosis of FGN in renal biopsy specimens.

摘要

纤维状肾小球肾炎 (FGN) 是一种罕见的原发性肾小球疾病。FGN 的组织学和组织化学特征与其他肾小球疾病重叠,目前尚未确定用于诊断 FGN 的独特组织学生物标志物。我们分析了患者活检标本中肾小球的蛋白质组内容,发现 DnaJ 热休克蛋白家族 (Hsp40) 成员 B9 (DNAJB9) 是 FGN 肾小球中第四丰富的蛋白质。与淀粉样变性肾小球相比,FGN 肾小球中 DNAJB9 蛋白的表达水平高出 6 倍以上。桑格测序和蛋白质序列覆盖图谱显示,沉积在 FGN 肾小球中的 DNAJB9 蛋白没有任何主要的序列或结构改变。值得注意的是,我们在所有 FGN 患者中均检测到了 DNAJB9,但在健康肾小球或 19 种非 FGN 肾小球疾病中均未检测到。我们还观察到 DNAJB9 与 Ig 的共沉积。总之,这些发现表明 DNAJB9 是 FGN 的标志物,具有 100%的灵敏度和 100%的特异性。FGN 中 DNAJB9 过度表达的幅度和特异性表明该蛋白在 FGN 发病机制中具有作用。有了这些证据,我们提出 DNAJB9 是快速诊断肾活检标本中 FGN 的有力生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/5748911/02b95d08ddc5/ASN.2017030306absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/5748911/02b95d08ddc5/ASN.2017030306absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/5748911/02b95d08ddc5/ASN.2017030306absf1.jpg

相似文献

1
DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.DNAJ 热休克蛋白家族 B 成员 9 是纤维状 GN 的新型生物标志物。
J Am Soc Nephrol. 2018 Jan;29(1):51-56. doi: 10.1681/ASN.2017030306. Epub 2017 Nov 2.
2
Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).纤维状肾小球肾炎和 DNAJ 同源物亚家族 B 成员 9(DNAJB9)。
Kidney360. 2020 Jul 8;1(9):1002-1013. doi: 10.34067/KID.0002532020. eCollection 2020 Sep 24.
3
Immunoglobulin-Negative DNAJB9-Associated Fibrillary Glomerulonephritis: A Report of 9 Cases.免疫球蛋白阴性 DNAJB9 相关纤维状肾小球肾炎:9 例报告。
Am J Kidney Dis. 2021 Mar;77(3):454-458. doi: 10.1053/j.ajkd.2020.04.015. Epub 2020 Jul 23.
4
DnaJ Homolog Subfamily B Member 9 Is a Putative Autoantigen in Fibrillary GN.DNAJ 同源物亚家族 B 成员 9 是纤维状肾小球肾炎的潜在自身抗原。
J Am Soc Nephrol. 2018 Jan;29(1):231-239. doi: 10.1681/ASN.2017050566. Epub 2017 Nov 2.
5
Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series.DNAJB9 阳性纤维状肾小球肾炎肾移植后复发:病例系列研究。
Am J Kidney Dis. 2020 Oct;76(4):500-510. doi: 10.1053/j.ajkd.2020.01.018. Epub 2020 May 12.
6
Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.血清 DNAJB9 水平在纤维状肾小球肾炎患者中升高。
Kidney Int. 2019 May;95(5):1269-1272. doi: 10.1016/j.kint.2019.01.024. Epub 2019 Mar 1.
7
Clinicopathological characteristics and outcome of patients with fibrillary glomerulonephritis: DNAJB9 is a valuable histologic marker.纤维状肾小球肾炎患者的临床病理特征和预后:DNAJB9 是一种有价值的组织学标志物。
J Nephrol. 2021 Jun;34(3):883-892. doi: 10.1007/s40620-020-00783-4. Epub 2020 Jun 18.
8
A case of juvenile-onset fibrillary glomerulonephritis diagnosed by mass spectrometry and immunohistochemistry of DNAJB9.一例通过DNAJB9的质谱分析和免疫组织化学诊断的青少年起病的纤维性肾小球肾炎病例。
CEN Case Rep. 2022 Nov;11(4):412-416. doi: 10.1007/s13730-022-00693-3. Epub 2022 Feb 23.
9
IgA-dominant glomerulonephritis with DNAJB9-negative fibrillar polytypic immunoglobulin deposits in the subepithelium.IgA 主导的肾小球肾炎,伴 subepithelium 中纤维状多克隆免疫球蛋白沉积,DNAJB9 阴性。
CEN Case Rep. 2023 Aug;12(3):323-328. doi: 10.1007/s13730-022-00759-2. Epub 2022 Dec 28.
10
New developments in the diagnosis of fibrillary glomerulonephritis.纤维状肾小球肾炎的诊断新进展。
Kidney Int. 2019 Sep;96(3):581-592. doi: 10.1016/j.kint.2019.03.021. Epub 2019 Apr 9.

引用本文的文献

1
Recurrent immunotactoid glomerulopathy in a kidney transplant recipient: Case report.肾移植受者复发性免疫触须样肾小球病:病例报告
Medicine (Baltimore). 2025 Aug 1;104(31):e43673. doi: 10.1097/MD.0000000000043673.
2
Fibrillary glomerulonephritis: an observational study of clinical-pathological features and outcomes in patients from a multi-institutional cohort.纤维性肾小球肾炎:一项对多机构队列患者临床病理特征及预后的观察性研究
Clin Kidney J. 2025 May 28;18(6):sfaf166. doi: 10.1093/ckj/sfaf166. eCollection 2025 Jun.
3
Fibrillary glomerulonephritis disease natural history and outcomes: a retrospective two centre cohort study.

本文引用的文献

1
Fibrillary glomerulonephritis: An apparent familial form?纤维性肾小球肾炎:一种明显的家族性形式?
Nephrology (Carlton). 2015 Jul;20(7):506-9. doi: 10.1111/nep.12447.
2
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.序列变异解读的标准与指南:美国医学遗传学与基因组学学会和分子病理学协会的联合共识推荐
Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.
3
Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis.
纤维性肾小球肾炎的疾病自然史及转归:一项回顾性双中心队列研究
BMC Nephrol. 2025 Jul 1;26(1):330. doi: 10.1186/s12882-025-04187-z.
4
Fibrillary Glomerulonephritis Diagnosis Is Enhanced by DNAJB9: Three Cases with Different Clinical, Anatomopathologic Features and Outcomes.DNAJB9增强了纤维性肾小球肾炎的诊断:三例具有不同临床、解剖病理特征及转归的病例
Pathophysiology. 2025 May 25;32(2):22. doi: 10.3390/pathophysiology32020022.
5
Therapeutic Challenges and New Era in Fibrillary Glomerulonephritis with the Introduction of DNAJB9: Experience from a Tertiary Nephrology Center.DNAJB9引入后纤维性肾小球肾炎的治疗挑战与新时代:来自三级肾脏病中心的经验
J Clin Med. 2025 May 26;14(11):3709. doi: 10.3390/jcm14113709.
6
Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review.纤维性肾小球肾炎与多发性骨髓瘤:一例报告及文献综述
Case Rep Oncol. 2025 Apr 4;18(1):554-562. doi: 10.1159/000545498. eCollection 2025 Jan-Dec.
7
Fibrillary Glomerulonephritis with Prevalent IgA Deposition Associated with Psoriasis.伴有银屑病的、以IgA沉积为主的纤维性肾小球肾炎
Indian J Nephrol. 2025 Jan-Feb;35(1):98-101. doi: 10.4103/ijn.ijn_93_23. Epub 2023 Aug 14.
8
Recurrent Fibrillary Glomerulonephritis Secondary to Chronic Lymphocytic Leukemia: Remission of Kidney Disease with Ibrutinib.慢性淋巴细胞白血病继发复发性纤维性肾小球肾炎:依鲁替尼使肾病缓解
Case Rep Nephrol Dial. 2024 Oct 15;14(1):164-170. doi: 10.1159/000539742. eCollection 2024 Jan-Dec.
9
An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes.关于与肾病综合征相关疾病的最新综合综述
Biomedicines. 2024 Oct 4;12(10):2259. doi: 10.3390/biomedicines12102259.
10
Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review.用于肾小球肾脏疾病的诊断、风险预测和治疗指导的非侵入性生物标志物:全面综述。
Int J Mol Sci. 2024 Mar 20;25(6):3519. doi: 10.3390/ijms25063519.
2014年命名法:淀粉样纤维蛋白与淀粉样变性的临床分类
Amyloid. 2014 Dec;21(4):221-4. doi: 10.3109/13506129.2014.964858. Epub 2014 Sep 29.
4
Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53.基因毒性应激/p53诱导的DNAJB9抑制p53的促凋亡功能。
Cell Death Differ. 2015 Jan;22(1):86-95. doi: 10.1038/cdd.2014.116. Epub 2014 Aug 22.
5
Rituximab treatment for fibrillary glomerulonephritis.利妥昔单抗治疗纤维样肾小球肾炎。
Nephrol Dial Transplant. 2014 Oct;29(10):1925-31. doi: 10.1093/ndt/gfu189. Epub 2014 May 27.
6
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.基于质谱的蛋白质组学对皮下脂肪抽吸物中系统性淀粉样变性的临床诊断与分型
Haematologica. 2014 Jul;99(7):1239-47. doi: 10.3324/haematol.2013.102764. Epub 2014 Apr 18.
7
Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis.基于组合蛋白质组学的临床检测在淀粉样变性诊断和分类中的应用。
J Mass Spectrom. 2013 Oct;48(10):1067-77. doi: 10.1002/jms.3264.
8
Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients.纤维状肾小球肾炎的长期肾脏疾病结局:27 例病例系列研究。
Am J Kidney Dis. 2013 Oct;62(4):679-90. doi: 10.1053/j.ajkd.2013.03.031. Epub 2013 Jun 4.
9
Outcome of fibrillary glomerulonephritis.纤维状肾小球肾炎的转归。
Swiss Med Wkly. 2012 May 2;142:w13578. doi: 10.4414/smw.2012.13578. eCollection 2012.
10
Fibrillary glomerulonephritis: a report of 66 cases from a single institution.纤维状肾小球肾炎:单中心 66 例报告。
Clin J Am Soc Nephrol. 2011 Apr;6(4):775-84. doi: 10.2215/CJN.08300910. Epub 2011 Mar 24.